Clinical Trial Update: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating acalabrutinib for relapsed or refractory autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia has posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-05-29